SFI
VRNA

Susquehanna Fundamental Investments’s Verona Pharma VRNA Stock Holding History

Susquehanna Fundamental Investments’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-12,354
Closed -$77K – 1616
2020
Q3 		$77K Buy
+12,354
New +$85.3K ﹤0.01% 1306

Other funds holding VRNA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Susquehanna Fundamental Investments's VRNA Position: Q4 2020 in Review

Susquehanna Fundamental Investments sold out of Verona Pharma (VRNA) in Q4 2020, closing a stake of 12,354 shares — an estimated $77K sold.

Susquehanna Fundamental Investments first reported a position in VRNA in Q3 2020 and held it in 1 quarter. The position peaked at $77K in Q3 2020. 35 funds tracked by Wall St. Rank hold VRNA as of Q4 2020.

  • Susquehanna Fundamental Investments reported no remaining Verona Pharma position as of Q4 2020 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 12,354 Verona Pharma shares in Q4 2020, an estimated $77K.
  • Susquehanna Fundamental Investments first reported a position in Verona Pharma in Q3 2020 and held it in 1 quarter.
  • Susquehanna Fundamental Investments's Verona Pharma position peaked at $77K in Q3 2020.
  • 35 funds tracked by Wall St. Rank held Verona Pharma as of Q4 2020.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2020, filed 16 Feb 2021.